Woodcock: Pharma, regulators have lessons to learn from COVID

When pharmaceutical companies, health care leaders and regulators finally get a chance to debrief and pull lessons learned from the coronavirus pandemic, a chief takeaway may revolve around the many missed research opportunities.

However, learnings from COVID-19 may one day lead to novel trial design and increased cooperation among these players promise a better path forward when speed and safety need equal consideration. This message was among many shared by a leading regulator in a 9 November audio interview with editors at the New England Journal of Medicine (NEJM).